Details of the Drug Reposition

General Information of This Drug (ID: DMJ38X9)

Drug Name
PEG-bHb-CO   DMJ38X9
Synonyms
Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cardiovascular disease DIS2IQDX BA00-BE2Z Phase 2/3 [1]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Sickle-cell disorder DISW25G5 3A51 Phase 2 [2]
Cerebral ischemia DISO250N 8B11 Phase 2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02490202) Efficacy and Safety of SANGUINATE for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)